Related Experiment Video
Updated: Jan 27, 2026

Bioluminescence-Based Tumor Quantification Method for Monitoring Tumor Progression and Treatment Effects in Mouse Lymphoma Models
Published on: July 7, 2016
The PI3Kδ inhibitor umbralisib may be a promising therapy for patients with relapsed/refractory marginal zone lymphoma: In the phase IIb UNITY-NHL trial, the drug elicited a response rate of 55%. In addition, patients had a 1-year progression-free survival rate of 71%, with manageable side effects.
The PI3Kδ inhibitor umbralisib may be a promising therapy for patients with relapsed/refractory marginal zone lymphoma: In the phase IIb UNITY-NHL trial, the drug elicited a response rate of 55%. In addition, patients had a 1-year progression-free survival rate of 71%, with manageable side effects.
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Alzheimer's Disease: Treatment
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Treatment Resistant Cancers
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
Treatment Strategies for Psychological Disorders
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...

